Our results showed the inhibitory effect of avasimibe on CCA in vivo and in vitro and demonstrated that avasimibe targets FoxM1/AKR1C1 signaling, an essential pathway in tumorigenesis and cancer progression. This evidence concerns the gene AKR1C1 and cholangiocarcinoma.